within Pharmacolibrary.Drugs.ATC.C;

model C01BG01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.34,
    Cl             = 0.043333333333333335,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0056,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.003,
    Tlag           = 600,            
    Vdp             = 0.0032,
    k12             = 160,
    k21             = 160
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01BG01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Moracizine is a class IC antiarrhythmic drug, previously used for the treatment of ventricular arrhythmias. It acts by inhibiting the fast inward sodium current in cardiac myocytes, thus slowing cardiac conduction. Moracizine was withdrawn from the U.S. market due to lack of superiority over other drugs and concerns about safety.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Howrie, DL, et al., &amp; Dittert, LW (1987). Disposition of moracizine (ethmozine) in healthy subjects after oral administration of radiolabelled drug. <i>European journal of clinical pharmacology</i> 32(6) 607–610. DOI:<a href=\"https://doi.org/10.1007/BF02455996\">10.1007/BF02455996</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3308487/\">https://pubmed.ncbi.nlm.nih.gov/3308487</a></p></li><li><p>Guo, WY, et al., &amp; Yang, JM (1993). [Pharmacokinetics of moracizine and moracizine sulfoxide in healthy volunteers]. <i>Zhongguo yao li xue bao = Acta pharmacologica Sinica</i> 14(5) 433–436. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8010035/\">https://pubmed.ncbi.nlm.nih.gov/8010035</a></p></li><li><p>Siddoway, LA, et al., &amp; Woosley, RL (1990). Clinical pharmacokinetics of moricizine. <i>The American journal of cardiology</i> 65(8) 21D–71D. DOI:<a href=\"https://doi.org/10.1016/0002-9149(90)91413-z\">10.1016/0002-9149(90)91413-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2407090/\">https://pubmed.ncbi.nlm.nih.gov/2407090</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01BG01;
